Skip to main
PSNL
PSNL logo

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 0%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Personalis Inc. has demonstrated a positive financial trajectory, highlighted by a 28% increase in share value following the announcement of Medicare coverage for its NeXT Personal MRD test, showcasing strong initial market acceptance in breast cancer. The company’s strategic decision to temper volume growth in Q3 was aimed at safeguarding margins while awaiting reimbursement, indicating prudent financial management in anticipation of increased demand. Furthermore, with a large commercial partner like Tempus expected to enhance marketing efforts and positive reimbursement decisions anticipated for additional indications, Personalis’s revenue outlook for 2026 and beyond appears promising, reflecting its potential growth opportunities in the personalized cancer treatment sector.

Bears say

Personalis Inc. faces a negative outlook primarily due to a downward revision of its revenue guidance for 2025, decreasing from a range of $70-$80 million to $68-$73 million, reflecting a year-over-year decline of 12% to 5%. The company has encountered challenges in its biopharma revenue, notably a slowdown attributed to logical issues with sample flow for minimal residual disease (MRD) testing and reimbursement delays for clinical sample testing. Additionally, significant ongoing losses, coupled with debt on the balance sheet, present concerns about the company’s ability to achieve and sustain profitability in the future.

Personalis Inc (PSNL) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 0% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Personalis Inc (PSNL) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.